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Abstract: While knowledge regarding the diagnosis and treatment of osteoporosis has expanded 
dramatically over the last few years, gaps in knowledge still exist with guidance lacking on the 
appropriate management of several common clinical scenarios. This article uses ﬁ  ctional clinical 
scenarios to help answer three challenging questions commonly encountered in clinical practice. 
The ﬁ  rst clinical challenge is when to initiate drug therapy in a patient with low bone density. 
It is estimated that 34 million America have low bone density and are at a higher risk for low 
trauma fractures. Limitations of using bone mineral density alone for drug therapy decisions, 
absolute risk assessment and evidence for the cost-effectiveness of therapy in this population are 
presented. The second clinical challenge is the prevention and treatment of vitamin D deﬁ  ciency. 
Appropriate deﬁ  nitions for vitamin D insufﬁ  ciency and deﬁ  ciency, the populations at risk for 
low vitamin, potential consequences of low vitamin D, and how to manage a patient with low 
vitamin D are reviewed. The third clinical challenge is how to manage a patient receiving drug 
therapy for osteoporosis who has been deemed a potential treatment failure. How to deﬁ  ne 
treatment failure, common causes of treatment failure, and the approach to the management of 
a patient who is not responding to appropriate osteoporosis therapy are discussed.
Keywords: osteoporosis, osteopenia, bisphosphonate, vitamin D, dual-energy X-ray absorp-
tiometry
Introduction
With the aging of society, the prevention and treatment of osteoporosis has become a 
more recognized concern. The widespread availability of bone density screening and 
the development of efﬁ  cacious therapies that increase bone density and reduce fracture 
risk have resulted in more patients being evaluated and managed for osteoporosis. 
Still, many challenging patient scenarios exist in clinical practice where guidance is 
lacking on appropriate management. This paper summarized three clinical scenarios 
that are frequently faced by primary care providers in practice and gives guidance on 
how to approach the management of these osteoporosis-related challenges. The ﬁ  rst 
challenge discusses the management of low bone density and when to consider the 
initiation of pharmacologic therapy. The second challenge is preventing and treating 
vitamin D deﬁ  ciency in the elderly. The third challenge is how to manage a patient 
that is deemed a potential treatment failure.
Clinical challenge # 1:  Low bone density – When 
to initiate drug therapy?
Clinical scenario
A 58-year-old Caucasian woman presents for follow-up of her central dual-energy 
X-ray absorptiometry (DXA) results that indicate low bone density (T-score lumbar 
spine = −1.8, T-score total hip = −1.6, and T-score femoral neck = −1.4). Her past 
medical history is signiﬁ  cant only for hypertension and mild gastroesophageal Clinical Interventions in Aging 2008:3(2) 316
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reflux disease for which she takes hydrochlorothiazide 
and esomeprazole orally once daily. Her family history is 
signiﬁ  cant for a mother who had a hip fracture at the age of 
85 years. She has smoked 1 pack of cigarettes per day for 
last 38 years and occasionally drinks alcohol. She does not 
routinely exercise. Her current weight is 65 kg and height is 
5 feet, 5 inches or 162.5 cm tall.
Approximately 10 million Americans have osteoporosis 
and an additional 34 million have low bone mass or osteo-
penia as deﬁ  ned by the World Health Organization (WHO) 
(Table 1) (Kanis and Gluer 2000; US Department of Health 
and Human Services 2004). This categorization is based 
solely on bone mineral density (BMD) T-scores, which is the 
number of standard deviations the patient’s BMD is below or 
above the mean BMD of a young, healthy, sex-matched refer-
ence population, using central DXA. BMD measurements are 
the most clinically used and accepted predictors of fracture 
risk. While BMD accounts for up to 70% of bone strength, 
there are limitations to using BMD alone for this purpose 
(Kanis et al 2001b; Schuit et al 2004; Siris et al 2004; Sornay-
Rendu et al 2005; Wainwright et al 2005). First, absolute 
BMD using DXA does not provide information regarding the 
quality of the bone. Bone strength depends on its mass, size, 
shape, degree of mineralization, microarchitecture, and the 
intrinsic properties of the materials that comprise the bone 
(Bouxsein 2005; Felsenberg and Boonen 2005). The two 
dimensional or areal depiction provided by DXA quantiﬁ  es 
only the mass, size, and degree of mineralization, limiting its 
ability to reﬂ  ect total bone strength and the bone’s risk for 
fracture (Kanis 2002). Alternative noninvasive technologies, 
such as 3-dimentional magnetic resonance microimaging and 
microcomputed tomography, are currently under investiga-
tion to improve bone strength measurement and fracture 
prediction (Felsenberg and Boonen 2005). Second, there are 
potential errors that exist when measuring BMD with central 
DXA. Improper placement of the patient on the instrument, 
patient movement during the scan, inaccurate calibration of 
the machine, the presence of vascular calciﬁ  cation or arthritic 
artifacts, and inappropriate interpretation of the DXA results 
by the practitioner can all negatively impact the value of the 
BMD results for fracture prediction.
While the WHO diagnostic criteria are helpful for estab-
lishing prevalence and incidence of disease, they cannot 
be relied upon alone to guide treatment decisions. BMD 
is only one of many factors that independently inﬂ  uences 
fracture risk. Age and previous history of fracture are strong 
independent predictors of fracture risk (Sornay-Rendu 
et al 2005). According to a study by Kanis and colleagues 
(2002), older postmenopausal women have up to a 7-fold 
higher risk for fracturing than younger postmenopausal 
women at the exact same BMD. BMD was measured in 
616 postmenopausal women who were then followed for a 
median of 5.6 years to determine the incidence of fractures. 
At baseline, 48% of women had osteopenia and 14.5% had 
osteoporosis. On follow-up, 73.1% of all fractures occurred 
in women without osteoporosis. Women with BMD in the 
osteopenia range and prevalent fracture were at higher 
risk for subsequent fracture than women with BMD in the 
osteoporotic range, but without prevalent fracture (Pasco 
et al 2006). Other known risk factors for osteoporosis are 
listed in Table 2.
There clearly exists a gap in deﬁ  ning and identifying 
those at both low and high risk for osteoporotic fractures. 
The decision to treat a patient to prevent fractures should 
ideally be based on a patient’s own absolute risk proﬁ  le. 
Absolute fracture risk can be more accurately predicted 
by utilizing risk factors such as age, prior fracture, and 
family history in combination with BMD values than on 
BMD criteria alone (Kanis et al 2001a, 2007). An absolute 
fracture risk assessment tool that can be used with or with-
out BMD measurement results is currently being designed 
by the WHO and holds promise to be a more sensitive 
assessment of facture risk (Kanis et al 2005). This much 
anticipated absolute risk assessment will use several easily 
identiﬁ  able clinical risk factors which act independently of 
bone mineral density to increase the risk of fracture. Fac-
tors such as age, previous fracture, family history of hip 
fracture, glucocorticoid use, current smoking, and alcohol 
use 2 drinks/day are being considered for the assessment 
tool. Similar to many other disease states that use a widely 
accepted and mainstream assessment tool to predict future 
clinical outcomes, this fracture assessment will provide 
an individual’s percent absolute probability of fracturing 
within the next 10 years. Clinician and third party payer 
acceptance of this tool are expected to be large barriers to 
its success, but there are several advantages that should be 
Table 1 World health organization bone mineral density (BMD) 
criteria (Kanis and Gluer 2000)a
Normal BMD  T-score  at  −1.0 and above.
Low bone mass (osteopenia)  BMD T-score between −1 and −2.5.
Osteoporosis  BMD T-score at or below −2.5.
  Women in this group with one or
  more fractures are considered to
 have  severe  osteoporosis.
Notes: aBased on BMD using DXA at the spine, hip, or wrist in white postmeno-
pausal women.Clinical Interventions in Aging 2008:3(2) 317
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considered. Having a simple and clearer treatment deci-
sion line is undoubtedly needed. Since central DXA is 
not always easily accessible in all parts of the world, this 
opens up alternative methods for determining fracture risk 
and treatment thresholds. For payers and medical societ-
ies providing new guidelines, this tool will simply deﬁ  ne 
absolute risk and any intervention thresholds can still be 
deﬁ  ned nationally based on accepted medical practices as 
well as the ability to pay.
For a Caucasian woman between the ages of 50–59 years, 
the prevalence of osteoporosis is approaching 15% and rises 
with increasing age. Another 30%–50% in this population 
has low bone density (osteopenia), which places them at 
increased risk for osteoporosis and fracture. Approximately 
half of the patients with fracture do not have osteoporosis 
based on WHO criteria (Melton et al 1993; Pasco et al 2006). 
The National Osteoporosis Risk Assessment (NORA) study 
evaluated the association between peripheral BMD and 
fracture risk over 1 year in over 200,000 postmenopausal 
women without a diagnosis of osteoporosis (Siris et al 2001; 
Miller et al 2002). Overall, 39.6% of the population evalu-
ated had BMD T-scores within the osteopenic range. While 
fracture risk was highest among women with osteoporosis, 
the majority of fractures overall (52%) occurred in the group 
of women with osteopenia (Siris et al 2004). These data 
support the fact that low bone density cannot be used as 
the sole determinant of fracture risk as many women with 
bone densities in the osteopenic range are at risk for low 
trauma fractures.
All guidelines consistently recommend initiating 
pharmacologic therapy in postmenopausal women with 
osteoporosis (T-score at or below −2.5) or with a low 
trauma fracture of the spine or hip. In addition, the National 
Osteoporosis Foundation (NOF) recommends that drug 
therapy be considered in postmenopausal women with BMD 
T-scores below −2.0 in the absence of risk factors and at a 
T-score below −1.5 with one or more major risk factors for 
fracture (National Osteoporosis Foundation 2003). In con-
trast, the North American Menopause Society recommends 
adding pharmacologic therapy if the T-score is between −2.0 
and −2.5 only in women with at least one additional major 
risk factor (North American Menopause Society 2006). Data 
from NORA suggest a peripheral BMD T-score of −1.8 or 
less accurately identiﬁ  es postmenopausal women at high risk 
for fracture risk at 1 year and can be useful to guide treatment 
decisions (Miller et al 2004).
Since low bone density is a silent risk factor for subse-
quent fracture, women of all ages should be counseled on 
preventing osteoporosis. A bone-healthy lifestyle is key 
(Lock et al 2006). The presence of modiﬁ  able risk factors 
(such as current smoking) should be carefully reviewed and 
addressed. Regular weight-bearing and muscle-strengthening 
exercises, as well as balance training exercises should be 
recommended to reduce the risk of falls. Women should 
be advised to limit alcohol intake to ideally less than one 
serving per day. Adequate vitamin D and calcium intake is 
paramount. A minimum intake of 1000–1200 mg of dietary 
and supplemental calcium and 400–1000 units of vitamin D is 
recommended for osteoporosis prevention/treatment (Stand-
ing Committee on the Scientiﬁ  c Evaluation of Dietary Ref-
erence Intakes 1997; Dawson-Hughes et al 2005; National 
Osteoporosis Foundation 2007).
The primary goal of pharmacologic therapy should be 
fracture prevention. Several medications are FDA-indicated 
for the prevention of osteoporosis. Studies have demonstrated 
improvements in BMD and bone turnover markers with these 
therapies; however, data regarding the effect on fracture risk 
is limited (Hosking et al 1998; Mortensen et al 1998). While 
improvements in BMD and bone turnover are important, 
changes in these parameters do not always directly correlate 
with fracture risk reduction (Sarkar et al 2002; Small 2005).
The oral bisphosphonates alendronate, risedronate, and 
ibandronate are FDA-indicated for both prevention and 
treatment of postmenopausal osteoporosis. Evidence from 
studies of postmenopausal women with osteoporosis has 
shown that all approved oral bisphosphonates signiﬁ  cantly 
increase BMD and reduce vertebral fracture risk (Black et al 
Table 2 Risk factors (besides low bone mass) for osteoporotic 
fracture in postmenopausal women
Major risk factors (independent of bone mass) 
  • Advanced  agea,b
  •  Personal history of fracture as an adult (after age 45 years)a,b
  •  History of low trauma facture in a ﬁ  rst-degree relativea,b
  •  Low body weight (less than 127 lbs or 58 kg)a,b
  • Current  smokera,b
  •  Use of systemic glucocorticoids (for 3 or more months)a,b
  • Rheumatoid  arthritisb
  • Alcohol  intake  2 servings per dayb
Additional risk factors 
  •  Recent falls or having a tendency to fall
  • Female
  •  Caucasian or Asian race
  • Estrogen  deﬁ  ciency before age 45 years
  • Dementia
  •  Lifelong low calcium intake
  •  Vitamin D deﬁ  ciency
  •  Low physical activity
Notes: aNational osteoporosis foundation; bTo be included in the WHO fracture 
risk assessment tool (National Osteoporosis Foundation 2003; Kanis et al 2005).Clinical Interventions in Aging 2008:3(2) 318
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1996; Harris et al 1999; Chesnut et al 2004). Alendronate and 
risedronate have also been shown to reduce the risk for hip 
fractures (Black et al 1996; McClung et al 2001). Studies of 
oral bisphosphonate therapy in postmenopausal women with 
bone densities in the osteopenic or normal range have typi-
cally not evaluated the effect on fracture risk (Hosking et al 
1998; Mortensen et al 1998). The fracture intervention trial 
with alendronate did enroll some postmenopausal women 
with osteopenia. In a subgroup analysis of this study, women 
with T-scores between −1.6 and −2.5 without fractures at 
baseline were shown to have a signiﬁ  cant reduction in verte-
bral fracture risk (Quandt et al 2005). Oral bisphosphonates 
are safe and generally well tolerated. Upper gastrointestinal 
symptoms such as dyspepsia are the most common side 
effects seen with oral bisphosphonate therapy. Patients need 
to adhere to the strict administration guidelines to minimize 
these effects.
Intravenous (IV) bisphosphonates (ibandronate and zole-
dronic acid) have not been studied in women with osteopenia 
and therefore are not FDA-indicated for the prevention of 
osteoporosis. However, they may be an option for osteopo-
rosis prevention in postmenopausal women with documented 
poor adherence, who cannot tolerate oral bisphosphonate 
therapy due to gastrointestinal side effects or cannot take 
oral therapy due to issues related to malabsoption. Infusion-
related, ﬂ  u-like symptoms tend to the most common side 
effects associated with IV bisphosphonate therapy (Delmas 
et al 2006; Black et al 2007).
Hormone therapy (HT) is approved only for the preven-
tion of postmenopausal osteoporosis. While HT reduces 
the risk of spine and hip fractures by 34%, its use resulted 
in increased risk for breast cancer, heart attack, stroke, and 
venous thromboembolism (VTE) (Rossouw et al 2002). 
Since the risks potentially outweigh the beneﬁ  ts, HT is no 
longer considered a ﬁ  rst line therapy option for osteoporosis 
prevention. In alliance with current FDA and North American 
Menopause Society recommendations, estrogens should be 
reserved to treat moderate to severe menopausal symptoms 
and should only be used for as short of time as possible 
(The North American Menopause Society 2006, 2007). HT 
should only be considered for osteoporosis prevention in 
postmenopausal women for whom other medications are 
considered to be unsuitable and after careful review of the 
risks and beneﬁ  ts.
Raloxifene is an estrogen agonist-antagonist (EAA) that 
is approved for the prevention and treatment of postmeno-
pausal osteoporosis. Raloxifene has been shown to increase 
femoral neck and spine BMD in postmenopausal women with 
normal to low bone density at baseline and to reduce the risk 
for spine factures by 50% in postmenopausal women with bone 
density in the osteoporotic range without baseline vertebral 
fracture (Ettinger et al 1999; Kanis et al 2003). Possible side 
effects include increases in hot ﬂ  ashes, and increased VTE and 
fatal stroke risk (Ettinger et al 1999; Wooltorton 2006). One 
potential beneﬁ  t of raloxifene is the prevention of breast can-
cer. The Raloxifene Use for The Heart (RUTH) trial showed 
that raloxifene reduced the relative risk of estrogen-receptor 
positive invasive breast cancer by 55% over a ﬁ  ve year period 
(Barrett-Connor et al 2006). Raloxifene is also FDA-indicated 
to reduce the risk for invasive breast cancer in postmenopausal 
women with osteoporosis (Vogel et al 2006).
Teriparatide (recombinant parathyroid hormone), a daily 
administered subcutaneous anabolic agent, is not FDA-
indicated for the prevention of osteoporosis in postmeno-
pausal women. However, in postmenopausal women with 
osteoporosis and prevalent fractures, teriparatide reduced 
the risk of vertebral fractures and nonvertebral fractures 
over a 19 month period (Neer et al 2001). Teriparatide is 
generally well tolerated and the most common side effects 
include transient hypercalcemia, leg cramps, and dizziness. 
The long-term safety of teriparatide is unknown and the use 
is limited to 2 years. Since teriparatide is not approved as a 
preventative agent, it should only be considered if no other 
agents are appropriate or tolerated by the patient.
Strontium ranelate is approved by the European Union 
for the prevention and treatment of postmenopausal osteo-
porosis. Strontium, a once daily oral product, has a novel 
mechanism of action acting on both bone resorption and bone 
formation. Studies have demonstrated a signiﬁ  cant increase 
in BMD in postmenopausal women with normal to low 
bone density (Reginster et al 2002; O’Donnell et al 2006). A 
pooled analysis of studies in postmenopausal women with at 
least one baseline vertebral fracture or nonvertebral fracture 
demonstrated a 37% reduction in vertebral fractures and a 
14% reduction in nonvertebral fractures (Meunier et al 2002, 
2004; Reginster et al 2002, 2005; O’Donnell et al 2006). The 
main side effects include diarrhea and headache. In addition, 
an increased risk for VTE has been reported (O’Donnell et al 
2006). Strontium is an alternative to oral bisphosphonates 
for the prevention of osteoporosis.
Pharmacologic therapy is indicated and considered cost-
effective for most postmenopausal women with BMD T-
scores at or below −2.5 or with a low trauma fracture of the 
hip, spine or wrist. The initiation of drug therapy for women 
who do not meet these criteria is controversial. Five years 
of alendronate therapy was found not to be cost-effective Clinical Interventions in Aging 2008:3(2) 319
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in postmenopausal white women with T-scores better than 
−2.5 and no additional risk factors (Schousboe et al 2005b). 
The societal cost per quality-adjusted life-year (QALY) 
gained was estimated at US$70,000–332,000 depending 
on age and BMD. The presence of additional independent 
risk factors for fracture would be needed to bring this 
value to below the commonly accepted cost per QALY of 
US$50,000. This study clearly demonstrated that treatment 
based only on low bone density was not cost effective. 
In a similar analysis, the same authors determined that 
alendronate therapy would be cost-effective in women with 
one or more prevalent vertebral deformities and osteopenia 
(Schousboe et al 2005a).
Management of this patient
Based on the WHO criteria, this patient has low bone mass or 
osteopenia. In addition to her low BMD, she has additional 
independent risks for fracture including a family history of 
osteoporosis in a primary degree relative and being a cur-
rent smoker. According to the NOF guidelines, this patient 
should be considered for pharmacologic therapy based on a 
T-score below −1.5 at the total hip and spine and the pres-
ence of at least one major risk factor. Based on her age of 58 
years, she is at a signiﬁ  cantly lower 10-year risk for fracture 
compared to an older woman with similar risk factors and 
BMD. However, she is probably at a high enough risk to 
warrant consideration of pharmacologic therapy. This is a 
prime example of a patient where the WHO’s absolute risk 
assessment tool will be valuable.
At minimum this patient should be educated on a 
healthy bone lifestyle with an emphasis on smoking cessa-
tion, exercise and adequate calcium and vitamin D intake. 
The decision to initiate pharmacological therapy should be 
made in conjunction with the patient. Adherence rates with 
these therapies tend to be low and poor adherence has been 
linked to poor outcomes (Siris et al 2006; Weycker et al 
2007). It is important that the patient fully understands any 
risks and expected beneﬁ  ts of therapy. If pharmacologic 
treatment is selected, an oral bisphosphonate would be the 
drug of choice. Drug treatment may not be life-long in this 
patient. Women without evidence of a low trauma fracture 
and who have responded well to bisphosphonate therapy 
with BMD T-scores maintained in the osteopenic range are 
being considered for a “drug holiday” with close monitoring. 
Studies have demonstrated prolonged suppression of bone 
turnover and maintenance of BMD in some women after 
discontinuation of alendronate therapy (Black et al 2006). If 
pharmacologic treatment is deferred, the patient can be safety 
monitored for signiﬁ  cant decreases in BMD with serial DXA 
scans or biomarkers of bone turnover.
Clinical challenge #2: Prevention/
management of vitamin D 
deﬁ  ciency
Clinical scenario
An 84-year-old African American woman presents for fol-
low-up of laboratory studies that were drawn at her last clinic 
visit after her central DXA bone density results revealed 
osteoporosis (T-score lumbar spine = −2.8, T-score total hip 
= −2.2, and T-score femoral neck = −2.4). Pertinent laboratory 
values were as follows: 25-hydroxyvitamin D (25-OHD) 
concentration = 22 nmol/L (9 ng/mL), complete blood count 
(CBC) = within normal limits, blood urea nitrogen (BUN) = 
2.9 mmol/L (8 mg/dL), serum creatinine (Scr) = 80 µmol/L 
(0.9 mg/dL), liver function tests (LFTs) = within normal 
limits, albumin = 35 g/L (3.5 g/dL), calcium = 2.3 mmol/L 
(9.2 mg/dL), phosphorous = 0.9 mmol/L (2.8 mg/dL), para-
thyroid hormone = 75 ng/L (75 pg/mL).
Adequate serum vitamin D concentrations are important for 
the maintenance of skeletal health and play a potential beneﬁ  cial 
role in extraskeletal organ systems as well. Vitamin D is impor-
tant for calcium homeostasis. Inadequate levels of vitamin D 
can lead to insufﬁ  cient calcium absorption and decreased serum 
calcium. To compensate, parathyroid hormone (PTH) secre-
tion is increased. In turn, PTH decreases calcium excretion in 
the kidneys and increases bone resorption to mobilize calcium 
stores in the bone, increasing serum calcium. Prolonged, severe 
vitamin D deﬁ  ciency can lead to poor bone mineralization and 
osteomalacia. Several studies have demonstrated a decrease in 
calcium absorption and an increase in PTH in the face of low 
vitamin D levels (Malabanan et al 1998; Thomas et al 1998; 
Heaney et al 2003). Low vitamin D levels have been associated 
with increases in bone turnover, low BMD, and an increased 
risk for fractures (LeBoff et al 1999). Vitamin D receptors are 
present within the muscle tissue (Pfeifer et al 2002; Bischoff 
et al 2003). Cross-sectional studies have demonstrated vitamin 
D levels correlate with markers of muscle strength and neu-
romuscular coordination (Dhesi et al 2002; Pfeifer et al 2002; 
Vieth 2005). In addition, studies have demonstrated an increase 
in falls in patients with low vitamin D concentrations (Stein 
et al 1999; Pasco et al 2004). More recently evidence supports 
inadequate concentrations of vitamin D may be involved in the 
pathogenesis of several disease states such as cancer, cardio-
vascular disease, diabetes, multiple sclerosis, and rheumatoid 
arthritis (Holick 2006; Lappe et al 2007; Martins et al 2007).Clinical Interventions in Aging 2008:3(2) 320
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Serum 25-OHD is the best indicator of vitamin D status. 
There continues to be debate as to the optimal serum con-
centrations of 25-OHD and there is no consensus on the 
recommended cut-points for deﬁ  ciency, insufﬁ  ciency and 
sufﬁ  ciency (Dawson-Hughes et al 2005; Bischoff-Ferrari 
et al 2006). Several studies have shown that serum concen-
trations of 25-OHD of at least 50–75 nmol/L (20–30 ng/ml) 
are necessary to maximize intestinal calcium absorption 
and minimize secondary hyperparathyroidism (Chapuy et al 
1997; Malabanan et al 1998; Heaney et al 2003; Greenspan 
et al 2005; Levis et al 2005). However, some evidence sug-
gests that optimal fracture and fall prevention occurs with a 
mean 25-OHD concentration of approximately 100 nmol/L 
(40 ng/ml) (Bischoff-Ferrari et al 2006). Most experts do 
agree that the risk for osteomalacia is increased when 25-
OHD concentrations fall below 20–25 nmol/L (8–10 ng/ml) 
(Hanley and Davison 2005). Based on these data reasonable 
cut-points that deﬁ  ne vitamin D deﬁ  ciency, insufﬁ  ciency and 
sufﬁ  ciency are summarized in Table 3.
Several studies have demonstrated a high prevalence 
of vitamin D deﬁ  ciency and insufﬁ  ciency regardless of the 
geographical location or latitude, age, or health status of the 
subjects. (van der Wielen et al 1995; Chapuy et al 1997; 
Thomas et al 1998; Harris et al 2000; Lips et al 2001; Vieth 
et al 2001; Greenspan et al 2005). A study of older adults in 
south Florida revealed a 39% prevalence of vitamin D insuf-
ﬁ  ciency (deﬁ  ned as a 25-OHD concentration 50 nmol/L or 
20 ng/mL) and a 9% prevalence of severe deﬁ  ciency (deﬁ  ned 
as a 25-OHD concentration 30 nmol/L or 12 ng/mL) (Levis 
et al 2005). In a study of general medical patients in Boston, 
57% were considered vitamin D deﬁ  cient (25-OHD 38 
nmol/L or 15 ng/mL) (Thomas et al 1998). In a subgroup of 
77 patients who were 65 years of age and had no identiﬁ  -
able risk factors for vitamin D deﬁ  ciency, the incidence of 
low vitamin D was still high at 42%. Vitamin D status was 
evaluated in a prospective cohort study of North American 
postmenopausal women receiving drug therapy for osteopo-
rosis (Holick et al 2005). The majority (91.5%) were white, 
and they were fairly evenly distributed geographically. The 
mean ± SD serum 25-OHD was approximately 75 nmol/L 
(30 ng/mL) in these women, with 52% of concentrations 
at 75 nmol/L (30 ng/mL), 8% 38 nmol/L (15 ng/mL), 
and 1% 23 nmol/L (9 ng/mL). In a multivariate analysis, 
eight variables were associated with low serum vitamin D 
concentrations in this population including age 80 years, 
nonwhite, BMI 30 kg/m2, medications that affect vitamin 
D metabolism, vitamin D supplementation 400 units/day, 
lack of exercise, lack of discussion with physician on impor-
tance of vitamin D and 12th grade education. There was 
no association with latitude.
The ﬁ  rst step in the systemic activation of vitamin D3 is 
through the conversion of cutaneous 7-dehydrocholesterol by 
exposure to ultraviolet B (UV-B) light. Synthesis of vitamin 
D3 can be reduced by factors that reduce the penetration of 
the UV-B rays into the skin such as sunscreen, clothing and 
darkly pigmented skin (Reginster 2005). Ethnic and racial 
groups with darker skin pigmentation may be at higher risk 
for vitamin D deﬁ  ciency (Harris et al 2000; Nesby-O’Dell 
et al 2002). Wintertime vitamin D status was evaluated in 
community-dwelling, low income elderly (Harris et al 2000). 
Twenty one percent of the black subjects had a 25-OHD level 
of 25 nmol/L (10 ng/mL) compared to only 11% of white 
subjects. The mean plasma 25-OHD was about 30% lower 
in the black subjects compared to the white subjects. Data 
from the third National Health and Nutrition Examination 
Survey (NHANES III) was used to examine the prevalence of 
vitamin D deﬁ  ciency among African American women and 
white women aged 15–49 years (Nesby-O'Dell et al 2002). 
The mean 25-OHD serum concentration was approximately 
45 nmol/L (18 ng/mL) for African American women and 
83 nmol/L (33 ng/mL) for white women. The prevalence 
of low vitamin D (defined as a 25-OHD concentration 
38 nmol/L (15 ng/mL) was 42% in African American 
women compared with only 4% in white women.
Vitamin D assays are expensive with a typical cost 
of over US$100 per test and there is concern regarding 
the variability in 25-OHD measurements, with different 
laboratories yielding vastly different results depending on 
the assay used (Binkley et al 2004; Glendenning and Fraser 
2005; Holick 2005; Leventis et al 2005). Therefore, routine 
screening of vitamin D status cannot be recommended at this 
time. However, a 25-OHD measurement should be consid-
ered in anyone at high risk for vitamin D deﬁ  ciency such as 
patients with documented low bone density, history of a low 
trauma fracture or frequent falls, medical conditions causing 
malabsorption (for example Celiac disease or inﬂ  ammatory 
bowel disease), history of unexplained muscle/bone pain, 
or on medications known to affect vitamin D metabolism 
Table 3 Suggested cut-points for serum 25-hydroxyvitamin D 
concentrations (Dawson-Hughes et al 2005; Holick 2006, 2007)
Category 25-hydroxyvitamin  D
Deﬁ  cient  25 nmol/L (10 ng/mL)
Insufﬁ  cient  26–74 nmol/L (11–29 ng/mL)
Sufﬁ  cient  75–125 nmol/L (30–50 ng/mL)a
Notes: aDo not exceed concentrations 250 nmol/L (100 ng/mL).Clinical Interventions in Aging 2008:3(2) 321
Clinical challenges in osteoporosis
(for example antiepileptic medications). In addition, a 
25-OHD measurement should be considered in all elderly 
patients and persons with dark pigmented skin that have 
minimal to no sun-exposure and/or are not taking a daily 
multivitamin or additional vitamin D supplements.
Several studies have demonstrated a beneﬁ  cial effect 
of vitamin D3 (typically in conjunction with adequate 
calcium intakes) on BMD, fractures, and falls (Chapuy 
et al 1992, 1994, 2002; Lips et al 1996; Dawson-Hughes et al 
1997; Pfeifer et al 2000; Bischoff et al 2003; Trivedi et al 
2003; Bischoff-Ferrari et al 2004; Flicker et al 2005; Broe 
et al 2007). The effects of calcium and vitamin D supple-
mentation on bone density and nonvertebral fractures were 
evaluated in a double-blind, placebo-controlled trial of 
389 healthy, ambulatory men and women over 65 years of 
age (Dawson-Hughes et al 1997). Subjects were randomly 
assigned to 500 mg calcium plus 700 units cholecalciferol 
(vitamin D3) or placebo. After 3 years, signiﬁ  cantly higher 
BMD at the femoral neck, lumbar spine and total body were 
noted. In addition, there was a statistically signiﬁ  cant 50% 
relative risk reduction in nonvertebral fractures with 11 
fractures occurring in the calcium-vitamin D group and 26 
occurring in the placebo group.
The effectiveness of oral cholecalciferol supplementation 
on the prevention of hip and nonvertebral fractures in adults 
(age 60 years) was evaluated in a meta-analysis of double 
blind, randomized, controlled trials. Due to heterogeneity, 
vitamin D trials were pooled according to doses used (high = 
700–800 units/day and low 400 units/day). Five trials eval-
uated hip fracture risk. The 3 high dose trials demonstrated 
a statistically signiﬁ  cant 26% relative risk reduction in hip 
fractures. For the two low dose trials, there was no signiﬁ  -
cant difference in hip fracture risk. Seven trials evaluated 
nonvertebral fracture risk with similar results. Pooled results 
from the 5 high dose trials revealed a statistically signiﬁ  cant 
23% relative risk reduction in nonvertebral fractures. There 
was no difference in nonvertebral fracture risk for the pooled 
results of two low dose trials. A signiﬁ  cant inverse relation-
ship between hip fracture and nonvertebral fracture risk and 
achieved 25-OHD levels was noted. The estimated number 
needed to treat (NNT) was 45 to prevent one hip fracture and 
27 to prevent one nonvertebral fracture.
Vitamin D supplementation may improve neuromuscular 
function in the elderly and possibly reduce their risk for falls 
(Pfeifer et al 2000; Bischoff et al 2003; Bischoff-Ferrari et al 
2004; Dhesi et al 2004). In a double-blind placebo-controlled 
study, a single 600,000 units intramuscular injection 
of ergocalciferol (vitamin D2) resulted in a statistically 
signiﬁ  cant, yet modest, improvement in aggregate functional 
performance time, choice reaction time and postural sway 
compared with placebo (Dhesi et al 2004). There was no 
difference in falls over the 6-month study. In a 12-week, 
double-blind randomized controlled trial of elderly women 
living in a long-stay geriatric care unit, 1200 mg calcium plus 
800 units cholecalciferol was shown to signiﬁ  cantly improve 
musculoskeletal function and reduce falls compared with 
calcium alone (Bischoff et al 2003). A meta-analysis of 5 
double-blind, randomized controlled trials representing 1237 
patients demonstrated a statistically signiﬁ  cant 22% reduc-
tion in falls with vitamin D treatment compared to calcium 
alone or placebo (Bischoff-Ferrari et al 2004). The estimated 
NNT to prevent one fall was 15 patients.
The trials evaluating vitamin D supplementation include 
mainly white subjects (Bischoff-Ferrari et al 2005). In one 
prospective, controlled trial of African American postmeno-
pausal women, calcium plus 2000 units/day cholecalciferol 
did not decrease the rate of bone loss compared with placebo. 
Fracture risk and falls were not evaluated in this trial (Aloia 
et al 2005). While mean serum 25-OHD levels signiﬁ  cantly 
increased from 19.3 to 34.8 ng/mL (p  0.001) in the 
vitamin D group, 40% of the women had 25-OHD serum 
concentrations 32 ng/mL. Based on the results of this study, 
it may not be appropriate to extrapolate data on the dosing 
of vitamin D from studies of mostly white subjects to other 
racial and ethnic groups.
Not all vitamin D studies have demonstrated a beneﬁ  cial 
effect on fractures and falls (Grant et al 2005; Porthouse et al 
2005; Jackson et al 2006; Law et al 2006; Lyons et al 2007). 
The Women’s Health Initiative Trial (WHI) did not show 
a reduction in fracture with calcium and vitamin D supple-
mentation. However, subjects were randomized to receive 
400 units/day cholecalciferol; a dose that did not demonstrate 
fracture risk reduction in the meta-analysis (Jackson et al 
2006). In addition, adherence to therapy was poor with only 
59% of subjects taking 80% or more of the assigned therapy 
at the end of the trial. When the results were analyzed exclud-
ing participants 6 months after nonadherence was detected, a 
statistically signiﬁ  cant 29% relative reduction in hip fractures 
was demonstrated. The Record Trial evaluated 800 units/day 
oral cholecalciferol, 1000 mg/day oral calcium, and the com-
bination for secondary prevention of low-trauma fractures in 
elderly subjects (Grant et al 2005). There was no signiﬁ  cant 
difference in the incidence of new, low-trauma fractures 
or falls between any of the groups. Adherence in this trial 
was also poor with only 54.5% of subjects still taking the 
therapy at 24 months. Vitamin D levels were obtained in Clinical Interventions in Aging 2008:3(2) 322
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only 60 subjects so the vitamin D status of the entire study 
population is unknown. In an open randomized controlled 
trial, elderly women with one or more risk factors for hip 
fracture received either 800 units/day oral cholecalciferol, 
1000 mg/day oral calcium, and educational information 
on calcium intake and fall prevention or just educational 
information (Porthouse et al 2005). Adherence rates in this 
study were also low (63% at 12 months); however, when 
they analyzed the data only using women taking medica-
tion, there still was no reduction in fractures. Similar to the 
previous study, no vitamin D levels were obtained so the 
vitamin D status of the study population was unknown. In the 
WHI study, the dose was probably too low to affect fracture 
risk. In the other two studies that used 800 units per day; 
low adherence rates could have contributed to the negative 
ﬁ  ndings. In addition, without data regarding the vitamin D 
status of the populations at baseline and after therapy, it is 
difﬁ  cult to interpret the results of these studies.
There is no consensus on the most appropriate vitamin 
D supplementation regimen to maintain vitamin D sufﬁ  -
ciency. The Institute of Medicine (IOM) currently recom-
mends 400 units/day vitamin D for adults 50–70 years of 
age and 600 units/day for people over the age of 70 years 
(Melton et al 1997). The National Osteoporosis Foundation 
Guidelines recommend intakes of 800–1000 units/day for 
all persons 50 years of age and older (National Osteoporo-
sis Foundation 2007). Several experts believe up to 1200 
units/day vitamin D3 is needed to maintain 25-OHD levels 
at 75–100 nmol/L (30–40 ng/ml) (Holick 2003; Heaney 
2004; Dawson-Hughes et al 2005; Grant and Holick 2005; 
Hanley and Davison 2005; Bischoff-Ferrari et al 2006). 
However, in the previously mentioned study of African 
American women, only 60% had sufﬁ  cient 25-OHD con-
centrations after supplementation at a dose of 2000 units/day 
for a year (Aloia et al 2005). Based on the meta-analysis, the 
minimum effective dose for preventing fractures appears to 
be 700–800 units/day (Bischoff-Ferrari et al 2005). Vitamin 
D has a wide margin of safety with hypercalcemia rarely 
occurring even at relatively high doses (Vieth 1999; Grant 
and Holick 2005). The IOM states the safe upper limit for 
vitamin D as 2000 units/day (Standing Committee on the 
Scientiﬁ  c Evaluation of Dietary Reference Intakes FaNB, 
Institute of Medicine 1997). In one study, doses as high as 
4000 units/day were administered for up to 6 months without 
adverse consequence (Vieth et al 2001). It is evident that a 
reevaluation of the current vitamin D recommendations is 
needed. A National Institute of Health conference recently 
evaluated the efﬁ  cacy and safety of vitamin D across all ages. 
A detailed report is awaiting publication and it is anticipated 
that the recommended upper tolerable limit and daily allow-
ance for vitamin D will be increased.
Very few foods are naturally high in or fortiﬁ  ed with 
vitamin D. Therefore, to reach recommenced intakes, 
supplementation will be needed. Nonprescription vitamin D 
can be found in combination with calcium, as an individual 
supplement, or within the typical multivitamin. It is best to 
choose a product that has cholecalciferol, as ergocalciferol 
is considered to be less potent at increasing 25-OHD levels 
(Trang et al 1998). The average incremental increase in serum 
25-OHD has been estimated at 1.2 nmol/L (0.48 ng/mL) for 
every 40 units of cholecalciferol given compared with only 
3 nmol/L (0.12 ng/mL) for ergocalciferol (Dawson-Hughes 
et al 2005). In addition, all the trials that demonstrated anti-
fracture efﬁ  cacy or reduction in falls have used cholecalcif-
erol. It is unknown if supplementation with ergocalciferol 
would have the same beneﬁ  ts. High dose vitamin D is cur-
rently only available in the United States as ergocalciferol 
and requires a prescription.
Based on safety and efﬁ  cacy data, it seems reasonable to 
recommend at least 800–1000 units cholecalciferol per day 
in all adults (Table 4). Higher doses may be needed in certain 
populations including ethnic and racial groups with darker skin 
pigmentation. If compliance is an issue, ergocalciferol 50,000 
units orally once a month with periodic 25-OHD monitor-
ing has been used clinically for the long-term prevention of 
vitamin D deﬁ  ciency (Holick 2007; Saab et al 2007). Another 
option would be oral cholecalciferol (ergocalciferol in the US) 
100,000 units every 4 months, which was shown to reduce 
vertebral and nonvertebral fractures without adverse effects in 
a study of community-dwelling men and women aged 65 years 
and over (Trivedi et al 2003). Patients that are vitamin D deﬁ  -
cient will require much higher doses of vitamin D to rapidly 
replete their stores into the sufﬁ  cient range (Mastaglia et al 
2006). Studies are lacking that evaluate treatment for vitamin 
D deﬁ  ciency. Various regimens tend to be used clinically. 
Prescription oral ergocalciferol 50,000 units once weekly for 
8 weeks or until levels are sufﬁ  cient followed by a maintenance 
Table 4 Suggested regimens for vitamin D supplementation 
in adults 50 years of age (Malabanan et al 1998; National 
Osteoporosis Foundation 2007)
Category 25-hydroxyvitamin  D
Deﬁ  cient  50,000 units oral ergocalciferol once weekly
  for 8 weeks or until sufﬁ  cient level obtained
Insufﬁ  cient  800–1000 units oral cholecalciferol daily
Sufﬁ  cient  800–1000 units oral cholecalciferol dailyClinical Interventions in Aging 2008:3(2) 323
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dose of 800–1000 units/day is a regimen that is frequently used 
in the United States (Malabanan et al 1998).
Management of this patient
It was appropriate to obtain a 25-OHD measurement in this 
patient due to the fact that she has a bone density test indicat-
ing osteoporosis, is African American and elderly. Based on 
her 25-OHD concentration of 23 nmol/L (9 ng/mL), she has 
vitamin D deﬁ  ciency and is at risk for osteomalacia. Possible 
causes for vitamin D deﬁ  ciency should be investigated (for 
example: medications known to interfere with vitamin D 
metabolism, symptoms consistent with Celiac Sprue, or other 
malabsorptive disease). Dietary and supplemental vitamin 
D consumption should be quantiﬁ  ed. Since this patient is 
African American, her dark pigmented skin could contribute 
to her vitamin D deﬁ  ciency, which means that her vitamin D 
requirements might be higher. This patient should initially 
receive treatment doses of vitamin D to replete her body stores. 
Prescription oral ergocalciferol 50,000 units once weekly for 
at least 8 weeks is typically used. A 25-OHD measurement 
should be repeated and if it is greater than or equal to 75 nmol/L 
(30 ng/mL), the patient can be switched to maintenance therapy 
with at least 1000 units/day of oral cholecalciferol.
Clinical challenge #3:   Treatment 
failure
Clinical scenario
A 78-year-old Hispanic woman has been receiving alendro-
nate 70 mg orally once weekly for 2 years for the treatment 
of osteoporosis. The patient states that she is tolerating the 
therapy without difﬁ  culty and has been compliant with the 
regimen as prescribed. She has not suffered a fracture and 
there is also no change in measured height or curvature of 
spine. A repeat central DXA test was performed and the 
results are as follows.
Baseline BMD
•  L1-L4 0.983 g/cm2, T-score –2.88
•  Left Total Hip 0.779 g/cm2, T-score –2.63
Repeat BMD 2 years later
• L1-L4  0.942  g/cm2, T-score –3.01: a 4.2% decrease 
compared to the prior test
•  Left Total Hip 0.760 g/cm2, T-score –2.70: a 2.5% 
decrease compared to the prior test
Least signiﬁ  cant change for this DXA machine
•  Lumbar spine (L1-L4) = 4.0%, Total hip = 3.4%
The ﬁ  rst issue is to deﬁ  ne failure to respond to therapy. 
While this may at ﬁ  rst seem relatively straightforward, it 
clearly is not. Any of 3 parameters can be used in making 
this determination: continuing loss of bone mass on therapy, 
failure of therapy to suppress biomarkers of bone turnover, 
or the occurrence of additional fractures on therapy. While 
all may provide important information, one must be aware 
of the pitfalls of using these criteria.
Serial BMD testing using central DXA is the standard 
of care for monitoring the response to therapy. In order to 
appropriately interpret the BMD results, the least signiﬁ  cant 
change (LSC) value for the DXA machine used must be 
known (Miller et al 1999b; Cummings et al 2000; Bonnick 
et al 2001). The LSC is the smallest change that is considered 
to be a real change on a speciﬁ  c DXA machine. This value is 
calculated by multiplying the precision error of the machine 
by 2.77. The LSC must be calculated on site for each indi-
vidual machine on a regular basis (ideally weekly or monthly) 
and can be found on the DXA report. The LSC should be 
calculated for the absolute BMD change in g/cm2 and not 
for the T-score or Z-score. Once the LSC for a particular 
DXA machine is known, serial measurements that are done 
on the same machine can then be interpreted properly. Serial 
BMD changes that meet or exceed the LSC are considered 
signiﬁ  cant changes (gains or losses), whereas BMD changes 
that are less than the LSC or that come from entirely different 
DXA machines cannot be interpreted as true BMD changes. 
In clinical trials, subjects whose BMD increased were shown 
to have the greatest reductions in fracture risk. However, sub-
jects whose BMD remained stable or decreased less than 4% 
were also shown to have signiﬁ  cant reduction in fracture risk 
and it was only those, whose BMD decreased signiﬁ  cantly, 
that had an unchanged fracture risk (Chapurlat et al 2005). 
Therefore, when serial BMD measurements are monitored, 
failure to respond to therapy is identiﬁ  ed only when BMD, 
measured on the same DXA machine, decreases more than 
the known LSC for that speciﬁ  c machine.
Biomarkers of bone turnover can also be used to assess 
responses to therapy (Rosen et al 1997; Greenspan et al 
1998; Miller et al 1999a). The most common biomarkers 
measured are urine n-telopeptides (NTX), urine or serum 
c-telopeptides (CTX), urine pyridinoline crosslinks, serum 
bone specific alkaline phosphatase (BSAP), and serum 
n-terminal propeptide of procollagen type 1 (P1NP). When 
using anti-resorptive therapy, one would expect suppression 
of biomarkers by 30% if pre-therapy values are available for 
comparison or to the lower end of the normal range when 
pre-therapy values are absent. A 30% suppression of NTX Clinical Interventions in Aging 2008:3(2) 324
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after initiation of anti-resorptive therapy has been shown to 
be associated with a signiﬁ  cant increase in both spine and 
hip BMD (Greenspan et al 1998). However, care must be 
taken in interpreting biomarkers because of the very signiﬁ  -
cant diurnal variations and day-to-day variations that may, 
in many cases, exceed the changes resulting from therapy. 
Because of the signiﬁ  cant variability inherent in their mea-
surements, it is best to collect specimens at the same time of 
day (second morning voided urine, fasting morning blood) on 
each occasion. Variation can also be reduced by averaging 
the result of two measurements or by pooling two samples 
on consecutive days. Because of this signiﬁ  cant variability, 
the exact role of biomarker assessment in monitoring therapy 
responses remains controversial.
Since low trauma fractures are the endpoint of interest 
in osteoporosis, it would seem that fractures occurring on 
therapy would be a sure indication of a therapeutic failure. 
The major published clinical trials have demonstrated 
vertebral and hip fracture reductions of 30% to 70% in 
patients on active osteoporosis therapy. (Black et al 1996; 
Ettinger et al 1999; Harris et al 1999; Chesnut et al 2000; 
McClung et al 2001; Neer et al 2001; Rossouw et al 2002; 
Meunier et al 2004; Black et al 2007). However, while the 
fracture risk was reduced by therapy, it was not entirely 
eliminated. Fractures continued to occur in both the treat-
ment and the placebo groups, albeit at a lower rate in the 
treatment groups. Patients who are placed on osteoporosis 
therapy are those who are identiﬁ  ed as being at high levels 
of risk. Risk reduction by improvements in BMD, bone 
remodeling, and bone quality is an achievable goal, whereas 
fracture elimination in a very high-risk population currently is 
not a realistic goal. Nonetheless, since low trauma fractures 
are generally a symptomatic endpoint, we often consider 
employing alternative or additional treatments when fractures 
continue to occur.
Once a failure to respond to therapy has been identiﬁ  ed, 
the next step is to determine the cause of the inadequate 
response (Harper and Weber 1998; Tannenbaum et al 2002; 
Lewiecki 2003). Extensive clinical experience and limited 
published data suggest that the most common causes of 
failure to respond to osteoporosis therapy are those listed in 
Table 5. Poor adherence, deﬁ  ned here as not taking the medi-
cation regularly or not at all, is probably the most common 
cause overall. It has been well demonstrated that less than 
50% of patients with osteoporosis remain on anti-resorptive 
therapy 1–1.5 years after therapy is initiated (Lo et al 2006; 
van den Boogaard et al 2006). It is not entirely clear from 
such studies how many patients discontinued medication due 
to side effects, but since serious side effects are relatively 
uncommon, it is likely that many patients simply stop their 
medications after brief periods of use. Deﬁ  cient calcium 
and/or vitamin D intake or absorption is another cause that is 
signiﬁ  cantly more widespread than is commonly appreciated 
(Holick et al 2005; Holick 2006). Inadequate circulating and 
interstitial calcium levels prevent adequate bone mineraliza-
tion and limit or prevent the beneﬁ  cial response to bone active 
agents. Co-morbid conditions that cause secondary bone loss 
and certain medications, some of which are summarized in 
Table 6, can also sabotage the response to otherwise effec-
tive bone therapy. It is only when all of the above have been 
carefully excluded that one can conclude that a therapy is 
simply not efﬁ  cacious in a speciﬁ  c patient.
The evaluation of patients suspected to be failing to 
respond to therapy should begin with a complete history, 
with an emphasis on determining medication adherence and 
assessing intake and absorption of calcium and vitamin D. A 
thorough physical examination should also be performed. If 
compliance remains an unresolved issue, pharmacy records 
Table 5 Causes of failure to respond to osteoporosis therapy
Compliance issues: Not taking medication or not taking medication correctly
Calcium nutritional deﬁ  ciency: Inadequate calcium intake or absorption
Vitamin D nutritional deﬁ  ciency: Inadequate vitamin D intake or absorption
Co-morbid conditions: Secondary bone loss
Medications: Secondary bone loss
Lack of efﬁ  cacy of existing therapy
Table 6 Selected secondary causes for osteoporosis (National 
Osteoporosis Foundation 2003; Painter et al 2006)
Disease states  Drugs
1° or 2° ovarian failure  Systemic glucocorticoids
Primary hyperparathyroidism  Excessive doses of levothyroxine
Thyrotoxicosis Most  anticonvulsants
Cushing’s syndrome  Depot medroxyprogesterone
 acetate  (DMPA)
Chronic liver disease-  Cytotoxic chemotherapy
(eg, Primary biliary cirrhosis)  Gonadotropin-releasing hormone
  (GnRH) agonists such as leuprolide
Celiac disease  Aromatase Inhibitors
Inﬂ  ammatory bowel disease 
Other malabsorptive states 
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may be requested or pill counts performed; testing for urine 
NTX may also be informative in this situation, since low 
to mid-normal values suggest that the patient is taking the 
medication, at least intermittently, whereas an elevated value 
adds evidence supporting noncompliance. In the patient who 
appears to be compliant, to be consuming adequate amounts of 
calcium and vitamin D and not to have obvious malabsorption, 
several key laboratory tests are recommended (Table 7). As 
discussed elsewhere in this manuscript, measurement of serum 
25-OHD concentrations allows one to identify either vitamin 
D deﬁ  ciency or vitamin D insufﬁ  ciency. An elevated or high 
normal serum PTH value associated with hypercalcemia 
indicates the presence of primary hyperparathyroidism. An 
elevated or high normal serum PTH value in association with 
a mid-normal or lower serum calcium level or low urinary cal-
cium excretion, suggests secondary hyperparathyroidism due 
to vitamin D deﬁ  ciency, calcium deﬁ  ciency, or chronic kidney 
failure. Measurement of tissue transglutaminase antibodies 
(for Celiac disease) should follow in any patient with low 
vitamin D levels, low urinary calcium excretion or second-
ary hyperparathyroidism not associated with chronic kidney 
failure. Depending upon the results, small bowel biopsies or 
radiographic studies for seronegative Celiac disease and other 
intestinal disorders should also be considered.
Bone biopsy and bone marrow biopsy seldom yield a 
diagnosis that is not already apparent after the above tests 
are completed. However, rare disorders such as systemic 
mastocytosis, may only be discovered by histological exami-
nation of the bone marrow. This procedure may therefore 
be indicated when the etiology of the bone disorder has 
otherwise remained elusive.
Management of the patient who is not responding to osteo-
porosis therapy may be relatively straightforward, depending 
on the underlying cause identiﬁ  ed. The noncompliant patient 
should be educated and encouraged to take the medication as 
directed. Repeat BMD testing in follow-up has been shown 
to improve adherence among patients on these chronic 
medications, possibly because of the positive feedback that 
assures them that they are receiving beneﬁ  t from being on the 
medication (Lo et al 2006). Patients with deﬁ  cient calcium 
or vitamin D nutrition should be encouraged to consume 
adequate amounts of calcium (1000–1200 mg/day) and 
cholecalciferol (800–1000 units/day). If the 25-OHD level 
is below 10 ng/mL, it is beneﬁ  cial to restore the depleted 
vitamin D reserves to sufﬁ  cient levels by administering a 
high-dose vitamin D regimen with repeated measurement of 
the 25-OHD after approximately 8 weeks of therapy.
When a nonresponding patient is determined to have good 
adherence, adequate calcium and vitamin D nutrition, and 
absence of co-morbid conditions that can cause bone loss, 
it may be reasonably concluded that the existing therapy 
in that patient is not efﬁ  cacious. In these circumstances, a 
change or augmentation of therapy should be considered. 
It is an important fact that there are currently no published 
studies that have examined the efﬁ  cacy of switching from 
one approved osteoporosis medication to another in a patient 
who appears to be failing to respond to the initial treatment. 
We therefore have no data that changing medications will 
be beneﬁ  cial in these circumstances. However, it may be 
reasonable at this juncture to consider changing to a stron-
ger medication or to a medication that has a different route 
of administration. Augmentation of therapy, by adding 
additional agents to existing therapy has engendered more 
interest in the research realm, but currently published data are 
inconclusive about the beneﬁ  t of this maneuver. Combining 
two anti-resorptive agents together, such as a bisphosphonate 
plus estrogen, raloxifene or calcitonin, results in slightly 
but statistically signiﬁ  cantly greater BMD increases than 
does one anti-resorptive agent alone (Lindsay et al 1999). 
However, there have been no published studies demonstrat-
ing that combinations of two anti-resorptive agents reduce 
the occurrence of low trauma fractures more than or even 
as well as anti-resorptive agent monotherapy. Combining 
an anti-resorptive agent with an anabolic agent has even 
greater theoretical appeal. However, two major studies 
utilizing the combination of alendronate and parathyroid 
hormone reported BMD gains that were generally similar to 
those seen with alendronate monotherapy and less than the 
BMD gains seen with parathyroid hormone monotherapy 
(Black et al 2003; Finkelstein et al 2003). Furthermore, no 
studies have adequately evaluated fracture reduction with 
combined anti-resorptive/anabolic agent regimens. Using 
anti-resorptive agents and anabolic agents sequentially, 
rather than concurrently, appears to have more promise, but 
remains under investigation (Black et al 2005)
Despite the absence of evidence that switching or adding 
agents provides any clear beneﬁ  t in the patient who is not 
Table 7 Suggested testing for the patient who is failing to 
respond to osteoporosis therapy
Serum testing 
  •  Calcium, phosphorus, alkaline phosphatase, creatinine, CBC, ESR
  •  25-OH D, PTH, TSH, SPEP, testosterone (men)
Urine testing 
  •  Calcium, N-telopeptides or other biomarkers
Abbreviations: CBC, complete blood count; ESR, erythrocyte sedimentation rate; 
25-OH D, 25-hydroxyvitamin D; PTH, parathyroid hormone; TSH, thyroid-stimulating 
hormone; SPEP, serum protein electrophoresis.Clinical Interventions in Aging 2008:3(2) 326
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responding to initial therapy, most practitioners would ﬁ  nd 
it unacceptable to do nothing when a patient is experiencing 
progressive bone loss or additional fractures. Based on clinical 
experience and the sparse data available in the literature, our 
suggestions for altering therapy in these circumstances are 
shown in Table 8. Patients who are failing to respond to raloxi-
fene, estrogen, strontium or calcitonin should, in most cases, be 
switched to oral bisphosphonate therapy. Those who have had 
previous gastrointestinal side effects with oral bisphosphonates 
can be changed to an IV bisphosphonate. IV bisphosphonates 
are also reasonable if one has any reason to believe that oral 
bisphosphonates are not being adequately absorbed into the 
circulation (eg, persistent elevation of urine n-telopeptides in 
a patient with good adherence on an oral bisphosphonate). In 
addition to being a good choice for primary therapy, teripara-
tide is also a good option for patients who have not responded 
to or who have not tolerated anti-resorptive therapy. Those who 
fail to respond to primary therapy with teriparatide should be 
changed to an oral or IV bisphosphonate.
Management of this patient
This patient had a clinically signiﬁ  cant reduction of BMD 
at the lumbar spine, exceeding the LSC, and to a T-score of 
−3.0, while compliant on therapy with an FDA-approved 
oral bisphosphonate. If not already done, this patient should 
be evaluated for possible secondary causes of bone loss. 
There are no published data that switching from an oral to an 
intravenous bisphosphonate is beneﬁ  cial in compliant patients 
that are tolerating oral therapy. If no correctable cause for this 
patient’s nonresponse to therapy can be identiﬁ  ed, the next 
step in this patient would be to consider discontinuing alendro-
nate therapy and initiating a 2-year course of teriparatide.
Conclusion
Signiﬁ  cant advances have been made in the evaluation and 
treatment of osteoporosis; however many clinical scenarios 
exist where consensus recommendations are lacking or 
controversy exists regarding appropriate management. 
This review summarizes three such clinical challenges and 
provides the primary care provider with practical informa-
tion to help them make rational choices when presented with 
similar patient scenarios in clinical practice.
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